Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry

Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry

We examined factors that may impact cabazitaxel treatment duration in a real-life setting in a compassionate use program, expanded access program, and prospective observational study in metastatic castration-resistant prostate cancer (mCRPC). Patients with mCRPC previously treated with docetaxel (N...

Full description

Bibliographic Details
Main Authors: Zafar Malik, Giuseppe Di Lorenzo, Angelika Pichler, Ugo De Giorgi, Simon Hitier, Evelyne Ecstein-Fraisse, Ayse Ozatilgan, Joan Carles
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Cancers
Subjects:
mCRPC
cabazitaxel
real-world
CUP
EAP
CAPRISTANA
Online Access:https://www.mdpi.com/2072-6694/12/4/995

Internet

https://www.mdpi.com/2072-6694/12/4/995

Similar Items